A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -65.69% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -74.19%. Over the past 30 days, the price of MBRX has leaped by -64.43%. And in the last five days, it has fallen by -52.58%.
Moleculin Biotech Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $10.35 on 03/11/24, while the lowest value for the same period was recorded at $0.66 on 02/11/25.
52-week price history of MBRX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Moleculin Biotech Inc’s current trading price is -94.36% away from its 52-week high, while its distance from the 52-week low is -11.46%. The stock’s price range during this period has varied between$0.66 and $10.35. The Moleculin Biotech Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.83 million for the day, a figure considerably higher than their average daily volume of 94360.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Moleculin Biotech Inc (MBRX) has experienced a quarterly decline of -75.07% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.97M and boasts a workforce of 18 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.1920, with a change in price of -1.7700. Similarly, Moleculin Biotech Inc recorded 88,505 in trading volume during the last 100 days, posting a change of -75.64%.
MBRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MBRX stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.05.
MBRX Stock Stochastic Average
Moleculin Biotech Inc’s raw stochastic average for the past 50 days is presently 0.67%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 1.18%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 2.10% and 1.87%, respectively.
